Queen's university Belfast and Elasmogen Limited
Lead Participant:
QUEEN'S UNIVERSITY BELFAST
Abstract
To develop new targeted nanomedicines for the treatment of cancers with unmet clinical need using variable New Antigen Receptor technology.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
Participant |
||
| QUEEN'S UNIVERSITY BELFAST |
People |
ORCID iD |